G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
Previous Symbol
CUSIPN/A
Phone919-213-9835
Debt
Debt-to-Equity RatioN/A
Current Ratio28.68
Quick Ratio28.68
Price-To-Earnings
Trailing P/E Ratio-12.19
Forward P/E Ratio-16.67
P/E GrowthN/A
Sales & Book Value
Annual Sales$520,000.00
Price / Sales3,111.80
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book13.22
Profitability
EPS (Most Recent Fiscal Year)($3.57)
Net Income$-60,120,000.00
Net MarginsN/A
Return on Equity-37.57%
Return on Assets-35.35%
Miscellaneous
Employees44
Outstanding Shares37,190,000
Market Cap$1.70 billion
OptionableOptionable
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.67) by $0.08. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
5 Wall Street analysts have issued 1 year price targets for G1 Therapeutics' shares. Their predictions range from $63.00 to $80.00. On average, they anticipate G1 Therapeutics' share price to reach $74.00 in the next year. This suggests a possible upside of 70.1% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.
What is the consensus analysts' recommendation for G1 Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (8/8/2018)
- 2. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
Has G1 Therapeutics been receiving favorable news coverage?
News coverage about GTHX stock has trended neutral recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. G1 Therapeutics earned a news impact score of 0.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Beigene (BGNE), Amarin (AMRN), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), Nektar Therapeutics (NKTR), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO) and Agios Pharmaceuticals (AGIO).
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Mr. Barclay A. Phillips, CFO, Sr. VP of Corp. Devel. & Sec. (Age 55)
- Mr. Terry L. Murdock, Sr. VP of Devel. Operations (Age 58)
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 54)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
- Dr. Jay C. Strum, Chief Scientific Officer (Age 54)
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.62%), BlackRock Inc. (5.50%), Bank of New York Mellon Corp (3.79%), Franklin Resources Inc. (3.13%), JPMorgan Chase & Co. (1.59%) and JPMorgan Chase & Co. (1.43%). Company insiders that own G1 Therapeutics stock include Clay Thorp, Fredric N Eshelman, Jay Strum, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.
Which institutional investors are selling G1 Therapeutics stock?
GTHX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Russell Investments Group Ltd., Emerald Advisers Inc. PA, Victory Capital Management Inc. and Birchview Capital LP. Company insiders that have sold G1 Therapeutics company stock in the last year include Clay Thorp, Jay Strum, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Insider Buying and Selling for G1 Therapeutics.
Which institutional investors are buying G1 Therapeutics stock?
GTHX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC, BlackRock Inc., Emerald Mutual Fund Advisers Trust, JPMorgan Chase & Co., JPMorgan Chase & Co., BB Biotech AG and Trexquant Investment LP. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $43.51.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $1.70 billion and generates $520,000.00 in revenue each year. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.
What is G1 Therapeutics' official website?
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (NASDAQ GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
